Infliximab treatment for a patient with refractory Kawasaki disease.
10.3345/kjp.2006.49.9.987
- Author:
Hyo Jung YU
1
;
Soo Jin LEE
;
Sejung SOHN
Author Information
1. Department of Pediatrics, College of Medicine, Ewha Womans University, Seoul, Korea. sohn@ewha.ac.kr
- Publication Type:Case Report
- Keywords:
Mucocutaneous lymph node syndrome;
Tumor necrosis factor-alpha;
Infliximab
- MeSH:
Aneurysm;
Coronary Vessels;
Fever;
Humans;
Immunoglobulins;
Immunoglobulins, Intravenous;
Infant;
Male;
Methylprednisolone;
Mucocutaneous Lymph Node Syndrome*;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Korean Journal of Pediatrics
2006;49(9):987-990
- CountryRepublic of Korea
- Language:English
-
Abstract:
Intravenous immunoglobulin (IVIG) infusion is an effective therapy for acute Kawasaki disease (KD). Nonetheless, approximately 10 percent to 20 percent of patients have persistent or recrudescent fever despite IVIG treatment, leading to a higher risk for coronary artery aneurysms (CAA). This unresponsiveness may pose a challenge to the clinicians. Tumor necrosis factor-alpha levels are elevated in the acute phase of the disease, especially in patients who develop CAA. We report a 10-month-old male with KD who failed to respond to multiple doses of IVIG and methylprednisolone and who then was treated with infliximab (5 mg/kg single dose). After infliximab treatment, he became afebrile with normalization of inflammatory markers and no further progression of CAA.
